PMID- 16200596
OWN - NLM
STAT- MEDLINE
DCOM- 20051108
LR  - 20151119
IS  - 0004-3591 (Print)
IS  - 0004-3591 (Linking)
VI  - 52
IP  - 10
DP  - 2005 Oct
TI  - Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to 
      predict joint space narrowing in knee osteoarthritis.
PG  - 3160-7
AB  - OBJECTIVE: To determine whether baseline or serial plasma concentrations of 
      stromelysin (matrix metalloproteinase 3 [MMP-3]) protein might distinguish 
      subjects with progressive radiographic knee osteoarthritis (OA) from those with 
      stable disease. METHODS: Subjects were 120 women with unilateral knee OA who 
      participated in a 30-month randomized, placebo-controlled trial of structure 
      modification with doxycycline. Anteroposterior views of both knees in a 
      semiflexed position were obtained at baseline, 16 months, and 30 months. Subjects 
      were selected to obtain comparisons of plasma MMP-3 levels between 60 progressors 
      (21 taking doxycycline, 39 taking placebo) and 60 nonprogressors (30 taking 
      doxycycline, 30 taking placebo) with respect to medial joint space narrowing 
      (JSN) in the index knee. Each group consisted of 30 subjects who exhibited 
      significant increases in knee pain. Blood samples were obtained semiannually for 
      MMP-3 assay. RESULTS: Subjects in the placebo group whose MMP-3 concentration was 
      in the upper tertile of the baseline distribution showed a 4-fold increase in the 
      odds of progression of JSN as compared with the lower tertile (odds ratio 4.12, P 
      = 0.037). Baseline MMP-3 levels were unrelated to knee pain. The within-subject 
      mean of serial MMP-3 concentrations was associated with concurrent JSN in the 
      placebo group over the 0-16-month interval (b = 0.18 mm/SD increase in the mean 
      MMP-3, P < 0.01) and over the 16-30-month interval (b = 0.15, P < 0.05). Similar 
      evidence of concurrent validity was found in the placebo group for the maximum of 
      intercurrent MMP-3 values. CONCLUSION: The baseline MMP-3 level was a significant 
      predictor of JSN in this pilot study. Moreover, serial plasma MMP-3 levels 
      reflected concurrent JSN in the placebo group over the 30-month period of 
      observation.
FAU - Lohmander, L Stefan
AU  - Lohmander LS
AD  - Lund University, Lund, Sweden.
FAU - Brandt, Kenneth D
AU  - Brandt KD
FAU - Mazzuca, Steven A
AU  - Mazzuca SA
FAU - Katz, Barry P
AU  - Katz BP
FAU - Larsson, Staffan
AU  - Larsson S
FAU - Struglics, Andre
AU  - Struglics A
FAU - Lane, Kathleen A
AU  - Lane KA
LA  - eng
GR  - P60-AR-20582/AR/NIAMS NIH HHS/United States
GR  - R01-AR-43348/AR/NIAMS NIH HHS/United States
GR  - R01-AR-43370/AR/NIAMS NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arthritis Rheum
JT  - Arthritis and rheumatism
JID - 0370605
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Biomarkers)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - N12000U13O (Doxycycline)
SB  - IM
MH  - Anti-Bacterial Agents/administration & dosage
MH  - Biomarkers/blood
MH  - Doxycycline/administration & dosage
MH  - Female
MH  - Humans
MH  - Knee Joint/*pathology
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Osteoarthritis, Knee/*blood/drug therapy/*pathology
MH  - Predictive Value of Tests
EDAT- 2005/10/04 09:00
MHDA- 2005/11/09 09:00
CRDT- 2005/10/04 09:00
PHST- 2005/10/04 09:00 [pubmed]
PHST- 2005/11/09 09:00 [medline]
PHST- 2005/10/04 09:00 [entrez]
AID - 10.1002/art.21345 [doi]
PST - ppublish
SO  - Arthritis Rheum. 2005 Oct;52(10):3160-7. doi: 10.1002/art.21345.